Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Cited by 187 Publications

Cancer Discov, 2019, 9(6):722-737

PubMed: 31015319 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):519-533

PubMed: 30889383 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 555(7696):387-391

PubMed: 29513652 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Nature, 2018, 560(7716):117-121

PubMed: 30022168 ( click the link to review the publication )

Cell, 2018, 173(4):972-988

PubMed: 29656893 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Cancer Discov, 2018, 8(8):988-1005

PubMed: 29880585 ( click the link to review the publication )

Nature, 2017, 549(7673):548-552

PubMed: 28959974 ( click the link to review the publication )

Nature, 2017, 550(7676):360-365

PubMed: 28976962 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31437-X

PubMed: 29290468 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Cell Metab, 2014, 19(6):1034-41

PubMed: 24814482 ( click the link to review the publication )

Science, 2013, 339(6120):700-4

PubMed: 23306437 ( click the link to review the publication )

Nat Methods , 2013, 10(10):981-4

PubMed: 23955771 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell, 2011, 145(4):529-42

PubMed: 21565612 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1307

PubMed: 30898999 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(11):5634-5647

PubMed: 31006810 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-1673

PubMed: 30733193 ( click the link to review the publication )

Cancer Res, 2019, 79(8):2031-2041

PubMed: 30824588 ( click the link to review the publication )
Int J Cancer, 2019, 144(7):1685-1696

PubMed: 30478958 ( click the link to review the publication )

Int J Cancer, 2019, 144(5):1092-1103

PubMed: 30152517 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):90

PubMed: 30786932 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(2):431-445

PubMed: 30401718 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(1):42-53

PubMed: 30201826 ( click the link to review the publication )

Cancer Sci, 2019, 110(3):1064-1075

PubMed: 30663191 ( click the link to review the publication )

Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.06.022

PubMed: 31251940 ( click the link to review the publication )

J Biol Chem, 2019, 294(2):397-404

PubMed: 30478172 ( click the link to review the publication )

Breast Cancer Res Treat, 2019, 176(1):109-117

PubMed: 30989461 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-018-00717-9

PubMed: 30612311 ( click the link to review the publication )

Cell Cycle, 2019, 1-14

PubMed: 31238782 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):871-878

PubMed: 31075528 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 508(2):620-625

PubMed: 30522863 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(4):501-507

PubMed: 30737031 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(4):1098-1101

PubMed: 30277116 ( click the link to review the publication )

Mol Cell Biochem, 2019, 457(1-2):41-49

PubMed: 30993494 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):75-84

PubMed: 30431088 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(9):837-840

PubMed: 30013063 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2678

PubMed: 29992957 ( click the link to review the publication )

Cell Rep, 2018, 23(11):3127-3136

PubMed: 29898385 ( click the link to review the publication )

Cell Rep, 2018, 24(10):2629-2642

PubMed: 30184498 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.29747

PubMed: 29313488 ( click the link to review the publication )

Cancer Lett, 2018, 423:60-70

PubMed: 29526801 ( click the link to review the publication )
Br J Cancer, 2018, 119(11):1392-1400

PubMed: 30425352 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1167-1176

PubMed: 29626126 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2206-2216

PubMed: 29970481 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 150:24-34

PubMed: 29355504 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1837-1846

PubMed: 30323975 ( click the link to review the publication )

J Pharmacol Exp Ther, 2018, 365(1):117-126

PubMed: 29339456 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194611

PubMed: 29590171 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190717

PubMed: 29298345 ( click the link to review the publication )

Anal Biochem, 2018, 543:132-139

PubMed: 29247608 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Blood, 2017, 130(26):2848-2859

PubMed: 29042365 ( click the link to review the publication )

Nat Protoc, 2017, 12(9):1951-1961

PubMed: 28837130 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3906-3921

PubMed: 28160604 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(8):1309-1319

PubMed: 28389374 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):514-522

PubMed: 28034904 ( click the link to review the publication )

Cancer Lett, 2017, 398:1-11

PubMed: 28385602 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2892-2901

PubMed: 28958991 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0740

PubMed: 28500233 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):45-58

PubMed: 27671334 ( click the link to review the publication )
Virology, 2017, 507:220-230

PubMed: 28456021 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(9):694-704

PubMed: 28886275 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(1):211-217

PubMed: 28487110 ( click the link to review the publication )

Int J Med Sci, 2017, 14(12):1292-1300

PubMed: 29104487 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13223-13239

PubMed: 28099939 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1467-1472

PubMed: 29296788 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103931-103951

PubMed: 29262611 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1357-1366

PubMed: 27820601 ( click the link to review the publication )

Blood, 2016, 127(1):139-48

PubMed: 26463424 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(5):2546-2557

PubMed: 27965414 ( click the link to review the publication )

Cancer Res, 2016, 76(9):2778-90

PubMed: 27197267 ( click the link to review the publication )

Theranostics, 2016, 6(11):1821-32

PubMed: 27570553 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.13620

PubMed: 27336789 ( click the link to review the publication )

Diabetologia, 2016, 59(11):2360-2368

PubMed: 27539148 ( click the link to review the publication )

Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

Gynecol Oncol, 2016, 142(2):323-31

PubMed: 27282964 ( click the link to review the publication )

DNA Repair , 2016, 10.1016/j.dnarep.2016.06.001

PubMed: 27373144 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Mediators Inflamm, 2016, 2016:1984703

PubMed: 27524861 ( click the link to review the publication )

BMC Cancer, 2016, 16:621

PubMed: 27515310 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):851

PubMed: 27816051 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):725

PubMed: 27613518 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1516-26

PubMed: 26869042 ( click the link to review the publication )
PLoS One, 2016, 11(1):e0146031

PubMed: 26730949 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):234-240

PubMed: 27425251 ( click the link to review the publication )

Anal Biochem, 2016, 503:58-64

PubMed: 27036617 ( click the link to review the publication )

Target Oncol, 2016, 11(5):655-665

PubMed: 27188390 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7701-14

PubMed: 26713604 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13984-4001

PubMed: 26910887 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):772-81

PubMed: 27020103 ( click the link to review the publication )

Nanoscale, 2015, 7(6):2805-11

PubMed: 25584654 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.212

PubMed: 26073085 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.443

PubMed: 25619829 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(5):1236-46

PubMed: 25777962 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )

Front Microbiol, 2015, 6:878

PubMed: 26379653 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):262-8

PubMed: 25975349 ( click the link to review the publication )

BMC Cancer, 2015, 15:89

PubMed: 25884663 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):1090

PubMed: 25777417 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:3183-90

PubMed: 26124641 ( click the link to review the publication )

Dis Esophagus, 2015, 10.1111/dote.12299

PubMed: 25604309 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 460(2):183-90

PubMed: 25767076 ( click the link to review the publication )

Mol Cell Biochem, 2015, 400(1-2):153-62

PubMed: 25404465 ( click the link to review the publication )

J Breast Cancer, 2015, 18(4):329-38

PubMed: 26770239 ( click the link to review the publication )

Oncol Lett, 2015, 9(2):757-761

PubMed: 25621047 ( click the link to review the publication )

Princeton University, 2015, 88435/dsp01br86b5821

PubMed: ( click the link to review the publication )
Cell, 2015, 161(7):1592-605

PubMed: 26052046 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(11):7028-38

PubMed: 24861619 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5948-54

PubMed: 25145669 ( click the link to review the publication )

Cell Rep, 2014, 8(6):1808-18

PubMed: 25199834 ( click the link to review the publication )

Eur J Cancer, 2014, 50(15):2725-34

PubMed: 25128455 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

J Med Chem, 2014, 57(13):5579-601

PubMed: 24922587 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(2):R25

PubMed: 24625110 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2014, 127(23):5079-92

PubMed: 25248836 ( click the link to review the publication )

J Neuroscience, 2014, 34(28):9338-50

PubMed: 25009267 ( click the link to review the publication )

Arch Toxicol, 2014, 10.1007/s00204-014-1434-0

PubMed: 25526924 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):724-32

PubMed: 24356817 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):986-95

PubMed: 24552776 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.07.022

PubMed: 25139258 ( click the link to review the publication )

Mol Oncol, 2014, S1574-7891(14)00132-X

PubMed: 25028150 ( click the link to review the publication )

Oral Oncol, 2014, 50(9):825-31

PubMed: 25017803 ( click the link to review the publication )

Cancer Sci, 2014, 105(2):202-10

PubMed: 24219164 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1852(3):462-472

PubMed: 25483710 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2662-2673

PubMed: 25072752 ( click the link to review the publication )
Biochim Biophys Acta, 2014, 1844(10):1765-72

PubMed: 25062913 ( click the link to review the publication )

J Trans Med, 2014, 12(1):184

PubMed: 24965603 ( click the link to review the publication )

Mol Pharmacol, 2014, 9(4):e95649

PubMed: 24748377 ( click the link to review the publication )

Int J Oncol, 2014, 44(3):735-44

PubMed: 24378347 ( click the link to review the publication )

Cell Cycle, 2014, 12(11):1679-87

PubMed: 23656790 ( click the link to review the publication )

J Pharm Sci, 2014, 103(6):1913-20

PubMed: 24700236 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108731

PubMed: 25264618 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 10.1038/onc.2014.105

PubMed: 24769898 ( click the link to review the publication )

Medicine, 2014, 93(28):e294

PubMed: 25526472 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5003-15

PubMed: 23881923 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 12(7):529-34

PubMed: 23684799 ( click the link to review the publication )

Cancer Res, 2013, 72(11):2814-21

PubMed: 22447567 ( click the link to review the publication )

Cancer Res, 2013, 74(1):287-97

PubMed: 24240700 ( click the link to review the publication )

Oncogene, 2013, 32(47):5377-87

PubMed: 23934192 ( click the link to review the publication )

Cancer Lett, 2013, 343(2):217-23

PubMed: 24215868 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 32(1):95

PubMed: 24252502 ( click the link to review the publication )

FASEB J, 2013, 27(6):2316-27

PubMed: 23444429 ( click the link to review the publication )

Carcinogenesis, 2013, 34(4):739-49

PubMed: 23275151 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1179-92

PubMed: 23913164 ( click the link to review the publication )

DNA Repair , 2013, 12(12):1134-42

PubMed: 24210699 ( click the link to review the publication )

J Viral Hepat, 2013, 20(9):658-65

PubMed: 23910651 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):7086-95

PubMed: 23355489 ( click the link to review the publication )

J Mass Spectrom, 2013, 48(12):1285-90

PubMed: 24338883 ( click the link to review the publication )

DNA Repair (Amst), 2013, 12(6):394-402

PubMed: 23570906 ( click the link to review the publication )
Hepatology, 2012, 55(6):1840-51

PubMed: 22223166 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):417-23

PubMed: 22388737 ( click the link to review the publication )

EMBO Mol Med, 2012, 4(10):1087-96

PubMed: 22933245 ( click the link to review the publication )

Oncogene, 2012, 32(39):4634-45

PubMed: 23108394 ( click the link to review the publication )

Cancer Lett, 2012, 319(2):232-41

PubMed: 22266096 ( click the link to review the publication )

J Med Chem, 2012, 55(7):3011-20

PubMed: 22380680 ( click the link to review the publication )

Neoplasia, 2012, 14(3):169-77

PubMed: 22496617 ( click the link to review the publication )

DNA Repair , 2012, 11(6):537-49

PubMed: 22542292 ( click the link to review the publication )

Cancer Sci, 2012, 103(6):1045-50

PubMed: 22404155 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39824-33

PubMed: 21956491 ( click the link to review the publication )

J Biol Chem, 2012, 287(44):36777-91

PubMed: 22961983 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43720-9

PubMed: 23105099 ( click the link to review the publication )

PLoS One, 2012, 7(6):e39956

PubMed: 22768182 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2012, 84(3):815-21

PubMed: 22417805 ( click the link to review the publication )

ACS Nano, 2011, 5(11):9216-24

PubMed: 21962084 ( click the link to review the publication )

J Biol Chem, 2011, 286(14):12157-65

PubMed: 21285347 ( click the link to review the publication )

Mol Cell Biol, 2011, 31(12):2462-9

PubMed: 21482670 ( click the link to review the publication )

PLoS One, 2011, 6(11):e27183

PubMed: 22073281 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):962-8

PubMed: 21052091 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Features

A potent PARP inhibitor (currently in late stage clinical trials).

Targets

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
1 nM	5 nM

In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). ^[1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KP3.33	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmLaOEBl		Ml7CTWM2OD13LkewOUAh\|ryPIB?=	NF;aZVcyQDV3OU[xNy=>
KP6.3	MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml70OEBl		NF7EdHpKSzVyPUGwMlQzQCEQvF2g	MmP4NVg2PTl4MUO=
KP7.7	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnTZOEBl		NGG0N3VKSzVyPUW3JI5OKA>?	NHK1d3cyQDV3OU[xNy=>
KB2P3.4	NVLKT2Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3O4eVQh\A>?		M3H3T2lEPTB;MUK0JG0h	MWWxPFU2QTZzMx?=
KB2P1.21	NX\EU\|RTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmXMOEBl		MXnJR\|UxRTh7MEegcm0h	NVzUVVUzOTh3NUm2NVM>
U373-MG	NYKyO45iS3m2b4TvfIlkKEG\|c3H5	MX2xJO69VSB?	MVOyOEBp		NHLFclRKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7	NX:2NoRJOTh7NUS3NVI>
T98G	M2HMOGN6fG:2b4jpZ{BCe3OjeR?=	NXXvb\|BZOSEQvF2g	MX:yOEBp		NW\RTWxyUW6lcnXhd4V{KHKjZHnheIlwdiC\|ZX7zbZRqfmm2eR?=	M2fuTVE5QTV2N{Gy
U87-MG	M1zNT2N6fG:2b4jpZ{BCe3OjeR?=	NWr0XXE4OSEQvF2g	Ml;tNlQhcA>?		M3vqTmlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl?	M1XPO\|E5QTV2N{Gy
UVW	NVS4WlFvS3m2b4TvfIlkKEG\|c3H5	NWLKTGN5PTByIH7N	MYiyOEBp		MVTJcoNz\WG\|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6	NWDtU2FiOTh7NUS3NVI>
HeLa	NH3NVllHfW6ldHnvckBCe3OjeR?=	NE\lSIY2ODBibl2=	Ml;lOEBp		NYD6SnVxS2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu\|	NWfrdYdLOTh7NUS3NVI>
HeLa	NYHiWmpqTnWwY4Tpc44hSXO\|YYm=	MXOxJO69VSB?	M3ewUFI1KGh?		MoXwSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG\|ZTDhdpJme3R?	M3\1XlE5QTV2N{Gy
T98G	MlfMSpVv[3Srb36gRZN{[Xl?	NHzEc5YyKM7:TTC=	NHn6TmkzPCCq		MXHFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>?	NIHvRWgyQDl3NEexNi=>
L3	NEXVXGVEgXSxdH;4bYMhSXO\|YYm=	MVG1JO69VSB?	MU[5OkBp	NUnwW5NkTE2VTx?=	NIDPc\|BUcWewaX\pZ4FvfGy7IHnubIljcXS\|IHPlcIwhe3W{dnn2ZYw>	MlKyNlAyOjR2NUm=
Granta-519	NIr1OpBEgXSxdH;4bYMhSXO\|YYm=	M1\rWVUh\|ryPIB?=	MVO5OkBp	NGX5bIlFVVOR	M1XYdHNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?	MX6yNFEzPDR3OR?=
BT	NFiyN2VEgXSxdH;4bYMhSXO\|YYm=	NX;DOYRlPSEQvF2g	Mk\CPVYhcA>?	MoC1SG1UVw>?	MULTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt	MWmyNFEzPDR3OR?=
UPN2	NVrQZ3JXS3m2b4TvfIlkKEG\|c3H5	Mlm0OUDPxE1i	NFjHOYU6PiCq	MnPQSG1UVw>?	Ml7xV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	NHL4cJczODF{NES1PS=>
HBL-2	MW\DfZRwfG:6aXOgRZN{[Xl?	MVq1JO69VSB?	NWLXeZd3QTZiaB?=	NV:yfYI2TE2VTx?=	MnLnV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	NVvhWo9kOjBzMkS0OVk>
JVM-2	NGr4WZBEgXSxdH;4bYMhSXO\|YYm=	NFvvSG42KM7:TTC=	Mn:5PVYhcA>?	NYTlb5h6TE2VTx?=	Mnf4V4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	NYO5[HF4OjBzMkS0OVk>
Z138	M4PNfGN6fG:2b4jpZ{BCe3OjeR?=	NYrnWJZUPSEQvF2g	MXq5OkBp	M4\BO2ROW09?	MlX6V4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	NX\qb5B3OjBzMkS0OVk>
RWPE	NGXkd3hKdn[jc3n2[UBCe3OjeR?=	M4n1[VI2KM7:TR?=	MVO0PEBp	MoLYSG1UVw>?	MUnTbYdvcW[rY3HueIx6KHKnZIXj[ZMhTVKJLXTybZZmdiClZXzsJIlvfmG\|aX;u	NILpeG0zOTV5NUi2OS=>
VCaP	NXy1PXdJUW64YYPpeoUhSXO\|YYm=	NYm1S45YOjVizszN	NVHzPVc2PDhiaB?=	MX;EUXNQ	NX\pWnQ{W2mpbnnmbYNidnSueTDy[YR2[2W\|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>?	NHz5dYQzOTV5NUi2OS=>
Mouse H2AX−/− ES Cells	M3fMbmN6fG:2b4jpZ{BCe3OjeR?=	M1PKXFIvPSEQvF2=	NGHBeGozOCCq		M4TYUXNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=>	M1;CO\|I{OzV3NEi5
Mouse ATM−/− ES Cells	NFnX[HNEgXSxdH;4bYMhSXO\|YYm=	NFjRWIUzNjVizszN	M2K4d\|IxKGh?		NF;0fnRUcWewaX\pZ4FvfGy7IHnubIljcXS\|IHPlcIwhe3W{dnn2ZYw>	MXGyN\|M2PTR6OR?=
H1650	NFz6VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mor2NlAh\|ryP	NIjXdVYyPDRiaB?=		MlfsTWM2OD1zNT60O{DPxE1?	NFzOS\|AzOzJ\|OUiwPS=>
H1650PTEN+	NVr6eI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXSNlAh\|ryP	NHzMR2gyPDRiaB?=		Mn\kTWM2OD13MD64N{DPxE1?	M3:zV\|I{OjN7OEC5
PC-9	MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW[yNEDPxE1?	M3rOOFE1PCCq		MmnJTWM2OD13Lki4JO69VQ>?	NXy4XVJyOjN{M{m4NFk>
PC-9PTEN−	M4rxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVuzc4JmOjBizszN	MoKxNVQ1KGh?		NVTLPHh6UUN3ME22MlUzKM7:TR?=	MVyyN\|I{QThyOR?=
MDA-MB-231	NEXzWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWC1JIRigQ>?		NWfCb5hPUUN3ME22Mlkh\|ryP	M2rmdFI{PzZyNEm2
MDA-MB-468	NHzYSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYLvfmVrPSCmYYm=		MYXJR\|UxRTVwMDFOwG0>	NUfNPIlwOjN5NkC0PVY>
BT20	NU\GcJlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHf4emc2KGSjeR?=		NYXqPWJ1UUN3ME23Mlch\|ryP	NVn5NHA5OjN5NkC0PVY>
HCC1143	NHO3UZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NE\mN5Y2KGSjeR?=		MUnJR\|UxRTFzLkGg{txO	M3faeFI{PzZyNEm2
HCC1937	NEj4No9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnrwOUBl[Xl?		Moe1TWM2OD1zMj62JO69VQ>?	M33w[lI{PzZyNEm2
Hs578t	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1X0c\|Uh\GG7		NG\JSXhKSzVyPUWuOkDPxE1?	NFTP[XIzOzd4MES5Oi=>
Hs578t(si)	NF3mR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGLocmc2KGSjeR?=		NYfvSmZEUUN3ME23MlUh\|ryP	MlPvNlM4PjB2OU[=
BT474	NH7neJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXm1JIRigQ>?		NV3lS5l[UUN3ME2xPU45KM7:TR?=	M2ixdlI{PzZyNEm2
JIMT1	MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnToOUBl[Xl?		NV7vbVQ5UUN3ME23Mlch\|ryP	NUTYNWJqOjN5NkC0PVY>
SKBR3	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUi1JIRigQ>?		M2PjdGlEPTB;MUGuNUDPxE1?	NFW2V2EzOzd4MES5Oi=>
SUM159	MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYK1JIRigQ>?		M4nMZ2lEPTB;ND6yJO69VQ>?	NIPqW4UzOzd4MES5Oi=>
CAMA1	M37veGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnjSOUBl[Xl?		MUHJR\|UxRTF3Lkig{txO	NWHK[GFmOjN5NkC0PVY>
MCF7	NUm2U2xpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHLoOVU2KGSjeR?=		MoXXTWM2OD13Lkig{txO	NH7PdGYzOzd4MES5Oi=>
T47D	NX7BUlQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY[1JIRigQ>?		NX60cZh5UUN3ME25MlYh\|ryP	NF25O\|QzOzd4MES5Oi=>
HCT116	MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVuxNFAh\|ryP	M4\wclQ5KGh?	NY\m[o86TE2VTx?=	NHfxXWlKSzVyPUKuOUDPxE1i	MUCyOFU4Pzl2MR?=
SW1116	NGHHbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILTPFQyODBizszN	NX;wV5g{PDhiaB?=	MVnEUXNQ	NHTkclhKSzVyPUGwNEDPxE1?	MVuyOFU4Pzl2MR?=
HT29	M1\PNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV6xNFAh\|ryP	Mnv1OFghcA>?	MmPNSG1UVw>?	NELSSWFKSzVyPUG0Mlch\|ryP	M17IblI1PTd5OUSx
LoVo	NYqw[GFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXsd4oyODBizszN	Mn\jOFghcA>?	M1nsT2ROW09?	M2nSR2lEPTB;MUOuOEDPxE1?	NHHz[GUzPDV5N{m0NS=>
HCT-15	NFrLXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvWWGgyODBizszN	MX60PEBp	M{LiemROW09?	M1XBSGlEPTB;MUCg{txO	NETzWFkzPDV5N{m0NS=>
SW48	NFvCZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\nUI0yODBizszN	MkXzOFghcA>?	NEO1N\|hFVVOR	Mk\TTWM2OD17LkWg{txO	MnjpNlQ2Pzd7NEG=
C-1	NWOwXHJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnXdXMyODBizszN	NUPMRoxkPDhiaB?=	M4jETmROW09?	NWfiUIN[UUN3ME23MlYh\|ryP	MmjzNlQ2Pzd7NEG=
RKO	NYHJT4dRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUGxNFAh\|ryP	MljxOFghcA>?	NHzGboxFVVOR	NXTjendYUUN3ME21Mlkh\|ryP	Mk\ZNlQ2Pzd7NEG=
HCT116	NG\BfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXflPYl[OTByIN88US=>	NEjXNow1QCCq	NIfJfHhFVVOR	M2XjNnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	MmfPNlQ2Pzd7NEG=
SW1116	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLB[3YyODBizszN	M{HBZ\|Q5KGh?	MUnEUXNQ	MlywVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	MX2yOFU4Pzl2MR?=
HT29	MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fXeVExOCEQvF2=	NYDGSIRRPDhiaB?=	NGC5UYhFVVOR	NFvUcIJRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli	NFrrUIgzPDV5N{m0NS=>
LoVo	M1K4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPXNVAxKM7:TR?=	NYLPd3FnPDhiaB?=	MWDEUXNQ	M1XWdnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	NYHBfZNZOjR3N{e5OFE>
SW48	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6xNFAh\|ryP	MVi0PEBp	NHTZRWZFVVOR	NGPxTnBRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli	MVWyOFU4Pzl2MR?=
C-1	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXexNFAh\|ryP	MmrWOFghcA>?	NEixPHNFVVOR	MUHQc5RmdnSrYYTld{BUVi1\|ODDjfZRwfG:6aXPpeJkh	MUGyOFU4Pzl2MR?=
RKO	NEj1[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWWxNFAh\|ryP	MUm0PEBp	NUm3WVdDTE2VTx?=	M1mzUnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	NVvC[VY4OjR3N{e5OFE>
HCT116	MXjGeY5kfGmxbjDBd5NigQ>?	NXTKfZl5OTBibl2=	MYexNkBp	NXnScpRnTE2VTx?=	NG\LXW1KdmO{ZXHz[ZMhTE6DIHTveYJt\S2\|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i=	NU\FZZdJOjR3N{e5OFE>
HT29	MXXGeY5kfGmxbjDBd5NigQ>?	NYi1RXE1OTBibl2=	NEfEe2EyOiCq	MYLEUXNQ	NF\UW4VKdmO{ZXHz[ZMhTE6DIHTveYJt\S2\|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i=	MkTYNlQ2Pzd7NEG=
TE-6	NYjDSZpWTnWwY4Tpc44hSXO\|YYm=	NEK4bWc2KM7:TTC=	Mk\BNVIhcA>?	NXTxZ21UTE2VTx?=	MXPJcoR2[2W\|IFeyM20h[XK{ZYP0	MVGyOFIyQTF4NB?=
TE-6	MX7GeY5kfGmxbjDBd5NigQ>?	MYO1JO69VSB?	MWSyOEBp	M2WyW2ROW09?	NVe3foV{UW6lcnXhd4V{KGmwIHTveYJt\SC\|dILhcoQh[nKnYXvzJEhFW0K\|KR?=	NXG5[IRYOjR{MUmxOlQ>
Hep3B	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUe0NEDPxE1i	MVy3NkBp	MVnEUXNQ	MULTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=>	NHvEe44zPTB5Mke1Ni=>
Huh7	NXzu[o1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV20NEDPxE1i	NV3LW3d1PzJiaB?=	NWfzTm82TE2VTx?=	NYq5TY9kW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF?	M2\0dVI2ODd{N{Wy
Hep3B	M3rv[WZ2dmO2aX;uJGF{e2G7	Mn\VOFAh\|ryPIB?=	NU\mSpB7OjRiaB?=	NXnyc\|dNTE2VTx?=	NXjhW3RtUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR	MkSwNlUxPzJ5NUK=
Huh7	NEfje49HfW6ldHnvckBCe3OjeR?=	M3;rOVQxKM7:TTC=	NX61dHJnOjRiaB?=	MX;EUXNQ	M{PLSmlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?=	NFG2Wm8zPTB5Mke1Ni=>
Hep3B	NFXCfXlHfW6ldHnvckBCe3OjeR?=	NUO0ZlFIPDBizszNJC=>	NVzXc3ZPOjRiaB?=	NYfTfYtyTE2VTx?=	NEjnTpJKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG=	Mnu2NlUxPzJ5NUK=
Huh7	NIrM[YJHfW6ldHnvckBCe3OjeR?=	MnzlOFAh\|ryPIB?=	M3qxZlI1KGh?	MVPEUXNQ	MUTJcoR2[2W\|IHPlcIwh[XW2b4DoZYd6KHerdHigSGhOTVF?	NUXRNI52OjVyN{K3OVI>
SGC-7901	M3X3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV33fI5nOzEEoN88US=>	M3jre\|Q5KGh?	MVLEUXNQ	MYPCcI9kcyCxeHHsbZBt[XSrbj3pcoR2[2WmIHPlcIwh\GWjdHi=	M{L3ZVI2PzZ5MEe2
COLO-800	M1HGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofxTWM2OD1yLkS0NVY1KM7:TR?=	NVzsWlEyW0GQR1XS
EoL-1-	NHTpWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTBwNU[0OFYh\|ryP	MY\TRW5ITVJ?
NCI-H209	NITER4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnTU5M2UUN3ME2wMlkyPTV4IN88US=>	MVXTRW5ITVJ?
ES1	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLxN4dKSzVyPUGuNVE1ODhizszN	MXvTRW5ITVJ?
NKM-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHUTWM2OD1zLkK1N\|Q4KM7:TR?=	MXXTRW5ITVJ?
NTERA-S-cl-D1	NEfZNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnH2TWM2OD1zLkOzN\|QyKM7:TR?=	NXPnfY1IW0GQR1XS
MHH-ES-1	M{X2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLOTWM2OD1zLk[yNFY4KM7:TR?=	MVHTRW5ITVJ?
ES8	NFzub5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHSTWM2OD1zLkeyOFE1KM7:TR?=	M1vMSnNCVkeHUh?=
NCI-H720	NEjaZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\jTWM2OD1{LkKwOlk6KM7:TR?=	NIH6PWRUSU6JRWK=
EW-3	NUPHN2pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLacXhJUUN3ME2yMlI4PTN2IN88US=>	NXLSdodlW0GQR1XS
D-566MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTJwNES1Olgh\|ryP	MYjTRW5ITVJ?
697	NF\DXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJwOESxO\|Mh\|ryP	NFHlSHFUSU6JRWK=
ES5	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInB[YZKSzVyPUKuPFgyQDlizszN	MVfTRW5ITVJ?
COLO-684	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3LN4lKSzVyPUOuOVE3QTZizszN	MXzTRW5ITVJ?
ML-2	M4\oUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWm2U\|hRUUN3ME2zMlYxODV6IN88US=>	MorIV2FPT0WU
MC-IXC	NHK4cIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTNwNkOzPVMh\|ryP	M4HibXNCVkeHUh?=
DB	NXjZR3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTQWJFoUUN3ME2zMlY2PDR6IN88US=>	M{OwPXNCVkeHUh?=
HCC2218	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYO3S4lGUUN3ME2zMlc{OTB\|IN88US=>	MmnmV2FPT0WU
NCI-H510A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTNwOEK3NlQh\|ryP	MX7TRW5ITVJ?
NCI-H526	M1PXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXhTWM2OD1\|Lki2PVU5KM7:TR?=	NXPrfJRlW0GQR1XS
MV-4-11	NI\ZTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fjfmlEPTB;ND6xN\|M{PCEQvF2=	NGTUb5BUSU6JRWK=
PA-1	M3HYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTRwMkWyPUDPxE1?	MoXUV2FPT0WU
EW-22	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfZVJJKSzVyPUSuN\|U5PiEQvF2=	M2P4TXNCVkeHUh?=
KASUMI-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37PTWlEPTB;ND60NFExQSEQvF2=	M3P2[nNCVkeHUh?=
LU-139	M3HzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV:zc2RuUUN3ME20Mlc2QDJ7IN88US=>	MV7TRW5ITVJ?
SBC-1	NFH5OlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;PNmlKSzVyPUSuPFA6ODhizszN	M2\jcHNCVkeHUh?=
H4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DISmlEPTB;ND64PVQ1OyEQvF2=	Ml3wV2FPT0WU
EW-11	M1uzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17oe2lEPTB;NT6wPFA4OiEQvF2=	MnfxV2FPT0WU
NBsusSR	NHzHWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXnTWM2OD13LkGyNFU2KM7:TR?=	MWrTRW5ITVJ?
RPMI-8226	NUG2OmM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HjcGlEPTB;NT6xOVI1PCEQvF2=	M3\FXHNCVkeHUh?=
DEL	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTVwMkCwNFYh\|ryP	NHTsbVBUSU6JRWK=
ES4	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFSwTnBKSzVyPUWuOVE{QDlizszN	MknQV2FPT0WU
GCT	M{fOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPwTWM2OD13LkW2PFU3KM7:TR?=	MnrEV2FPT0WU
NCI-H1048	NYnvOnJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPhSYR4UUN3ME21Mlk4Ojd\|IN88US=>	M3\tTXNCVkeHUh?=
NCI-SNU-1	M{n5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGH1WG1KSzVyPU[uNFIzKM7:TR?=	NX7oR29TW0GQR1XS
ES7	MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfwOHdKSzVyPU[uNFM2PzdizszN	M1TsVXNCVkeHUh?=
SW982	MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3L2WmlEPTB;Nj6wPVE{PyEQvF2=	NFjofFhUSU6JRWK=
L-363	MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTZwM{O5O\|Qh\|ryP	MV3TRW5ITVJ?
HT-1080	NHe1dWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFGwd45KSzVyPU[uOFk3QDNizszN	NF7ucItUSU6JRWK=
HAL-01	NXHmVJZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXVdlVKSzVyPU[uOVExQSEQvF2=	M{f0SnNCVkeHUh?=
NB14	NWnTNFFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLKSo1KSzVyPU[uOlQxOzlizszN	MmHHV2FPT0WU
EW-13	NX;VOpB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPFeoNrUUN3ME22Mlc4PDJ2IN88US=>	M{jDTHNCVkeHUh?=
NY	MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTZwOUS2NFUh\|ryP	MkL3V2FPT0WU
NCI-SNU-5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojqTWM2OD15LkGwOFM{KM7:TR?=	MluyV2FPT0WU
MS-1	M3K0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzlZ3hYUUN3ME23MlE4PDl2IN88US=>	M4PMb3NCVkeHUh?=
EW-16	NH7Fe2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PlV2lEPTB;Nz6zNVg3OSEQvF2=	NYnOeHdFW0GQR1XS
LU-65	MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1S0fGlEPTB;Nz60PFQyPyEQvF2=	NFLFdZFUSU6JRWK=
HGC-27	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTdwN{KxO\|Mh\|ryP	MUPTRW5ITVJ?
CTB-1	M2TLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vLWWlEPTB;Nz63OlE4PSEQvF2=	NFq4fmlUSU6JRWK=
5637	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\ZTWM2OD15LkmyPFYh\|ryP	MXvTRW5ITVJ?
U251	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jrb2lEPTB;Nz65OFAyPiEQvF2=	NXLHSYMyW0GQR1XS
HOS	NHLZd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRThwMkOwNFch\|ryP	M3HMdXNCVkeHUh?=
DOHH-2	M13hOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\lTWM2OD16LkKzOVgh\|ryP	NWTtOZRlW0GQR1XS
EW-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13E[2lEPTB;OD6zNFA5QCEQvF2=	NXvFU4x6W0GQR1XS
BV-173	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPRWnVUUUN3ME24MlU2PTRizszN	NIKwWmJUSU6JRWK=
8-MG-BA	MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjh[HJnUUN3ME24MlY5QTh6IN88US=>	M{XWVHNCVkeHUh?=
NB69	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXm1coRRUUN3ME24MlcxQTJzIN88US=>	MXjTRW5ITVJ?
NCI-H69	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTlwOUC5OlEh\|ryP	MXfTRW5ITVJ?
RS4-11	NUnjeWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPSVHRKSzVyPUGxMlIzODhizszN	MkHvV2FPT0WU
ONS-76	NXz0ZZBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUm1eWYxUUN3ME2xNU4zQTR5IN88US=>	MnTWV2FPT0WU
SF539	NHnH[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHHcZJiUUN3ME2xNU41QDh7IN88US=>	NFXmW21USU6JRWK=
HuO-3N1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXSc28xUUN3ME2xNU42Pzl4IN88US=>	MmD3V2FPT0WU
NCI-H1651	MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTF{LkOxNVUh\|ryP	MUPTRW5ITVJ?
KARPAS-45	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXmTWM2OD1zMj6zO\|Yh\|ryP	M{jqd3NCVkeHUh?=
SK-NEP-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmm0TWM2OD1zMj60OlA6KM7:TR?=	M1nVeHNCVkeHUh?=
LAMA-84	NHfSVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\kTWM2OD1zMz6xNFk2KM7:TR?=	NGLBcXNUSU6JRWK=
NCI-H1155	M3TN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[yZ2pKSzVyPUGzMlI5PTZizszN	NV22[4pTW0GQR1XS
CTV-1	MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2zTWM2OD1zMz60OFUh\|ryP	M3zOU3NCVkeHUh?=
QIMR-WIL	NVP6dXlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XIdmlEPTB;MUOuO\|gyPCEQvF2=	NFrZZYVUSU6JRWK=
H9	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXKZ25PUUN3ME2xN{45PDd3IN88US=>	MXXTRW5ITVJ?
SK-MEL-1	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTF\|LkmzOFch\|ryP	Ml35V2FPT0WU
HD-MY-Z	M2\qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXftb\|hFUUN3ME2xOE4xPjN5IN88US=>	M2jldHNCVkeHUh?=
TI-73	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTF2LkKzOVYh\|ryP	NH;GRlFUSU6JRWK=
JVM-3	NIXuN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXOwOJlnUUN3ME2xOU42PzF4IN88US=>	MYXTRW5ITVJ?
D-247MG	M16wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDXTWM2OD1zNT61PVMh\|ryP	Mnj4V2FPT0WU
VA-ES-BJ	NIf6SoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPXfWh1UUN3ME2xOU43ODl5IN88US=>	NFvFVGlUSU6JRWK=
NOS-1	NGfheHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\1TWM2OD1zNT62OVIzKM7:TR?=	MnjmV2FPT0WU
MOLT-4	NH;z[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTF4Lke1NkDPxE1?	MY\TRW5ITVJ?
Mo-T	MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHFclRKSzVyPUG3MlA5PDlizszN	NED4NW1USU6JRWK=
NCI-H1770	M1TFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFviVJZKSzVyPUG3MlE2PDNizszN	NFy5W\|VUSU6JRWK=
COLO-320-HSR	NUC3RmlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TjTmlEPTB;MUeuNVgzPyEQvF2=	NFrUbFRUSU6JRWK=
TE-12	M1;2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUWx[4RUUUN3ME2xO{44ODV2IN88US=>	MXzTRW5ITVJ?
NCI-H82	M2i1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmr6TWM2OD1zNz64O\|I5KM7:TR?=	MX7TRW5ITVJ?
NEC8	NFP3[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1v3NmlEPTB;MUiuNVMyPiEQvF2=	M3;UeHNCVkeHUh?=
HSC-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnaOZZKSzVyPUG4Mlc1OTRizszN	NV31O2VnW0GQR1XS
NCI-H1092	NHrjTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LFNWlEPTB;MUiuO\|U6PSEQvF2=	MoPYV2FPT0WU
NCI-H292	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFi5fllKSzVyPUG5MlA1QDlizszN	MWfTRW5ITVJ?
L-428	NHPvUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Dt[WlEPTB;MUmuOVU6KM7:TR?=	MoD4V2FPT0WU
LU-134-A	NV7TWGdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF60eHFKSzVyPUG5MlU4OiEQvF2=	NX;jbWZYW0GQR1XS
GI-ME-N	MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmGxTWM2OD1zOT61O\|Q4KM7:TR?=	MXXTRW5ITVJ?
ALL-PO	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGL2O\|VKSzVyPUG5MlU6PzJizszN	MlftV2FPT0WU
D-283MED	NWr2[FY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTF7LkmxOUDPxE1?	NXe2Z5ptW0GQR1XS
D-423MG	M1HUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvUZVdKSzVyPUG5Mlk6PjdizszN	MnLqV2FPT0WU
CAKI-1	NGfpSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGL0R2lKSzVyPUKwMlIzOTlizszN	NY[1UWJwW0GQR1XS
ETK-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTJyLkK2NVUh\|ryP	NFPyUm5USU6JRWK=
G-402	NHrHfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLKZ\|l6UUN3ME2yNE42OzN2IN88US=>	MWXTRW5ITVJ?
HL-60	NYqyOoRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3lTWM2OD1{MT6xOlE{KM7:TR?=	MkLYV2FPT0WU
A2058	NGG1XHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnP1TWM2OD1{MT60OFc4KM7:TR?=	MVXTRW5ITVJ?
CHP-212	NYfFc2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTJzLkmwOVEh\|ryP	M4jPWHNCVkeHUh?=
KY821	M3O5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPqTWM2OD1{MT65O\|Uh\|ryP	NWD0V2lKW0GQR1XS
TYK-nu	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkH4TWM2OD1{Mj6wOlUyKM7:TR?=	M{HHfHNCVkeHUh?=
JVM-2	M3X1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHnboZOUUN3ME2yNk4zQTh\|IN88US=>	NEPrfVhUSU6JRWK=
KU812	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHXTWRKSzVyPUKyMlc{OTJizszN	MnuxV2FPT0WU
MKN28	Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHCWnBtUUN3ME2yNk46ODF3IN88US=>	NVzWT5J2W0GQR1XS
ECC10	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\tVmlEPTB;MkOuO\|QyKM7:TR?=	M3jrb3NCVkeHUh?=
BHT-101	NHzvfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDzfHc2UUN3ME2yOE4xODB6IN88US=>	NVr1SlNsW0GQR1XS
DU-4475	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWW2VItnUUN3ME2yOE4{OzN5IN88US=>	MU\TRW5ITVJ?
769-P	MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzHS4hLUUN3ME2yOE45PDZ4IN88US=>	NF34dJdUSU6JRWK=
HEC-1	M4jVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDSZW1KSzVyPUK1MlQ1PSEQvF2=	MX;TRW5ITVJ?
MOLT-13	NF3XO\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXTdlNKSzVyPUK1MlU{OzFizszN	MmDDV2FPT0WU
8505C	M4G0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJ4LkS5O\|ch\|ryP	NIDzTGVUSU6JRWK=
GB-1	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJ4LkexO\|Yh\|ryP	M1q1U3NCVkeHUh?=
SF126	M{DkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVr0V2FOUUN3ME2yOk44PjR6IN88US=>	MULTRW5ITVJ?
A4-Fuk	NXL5bVJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTJ5LkGyO\|Eh\|ryP	MlHTV2FPT0WU
OVCAR-8	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrXZ4VKSzVyPUK3MlE2OzlizszN	MojRV2FPT0WU
NCI-H1304	NGe5ZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLvVXB{UUN3ME2yO{42PCEQvF2=	NEezOW1USU6JRWK=
GR-ST	NGL2WodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HvZmlEPTB;MkiuNFQ4KM7:TR?=	MYTTRW5ITVJ?
G-401	NW\0OXFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTJ6LkWwPVYh\|ryP	NVjCV21qW0GQR1XS
LXF-289	M1TDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTJ6LkW2OVEh\|ryP	M{X2NXNCVkeHUh?=
DBTRG-05MG	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPITWM2OD1{OD65NlA1KM7:TR?=	M3jyfHNCVkeHUh?=
YKG-1	NUjEPWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPuV45KSzVyPUK5Mlg3QCEQvF2=	M{C1O3NCVkeHUh?=
GAMG	NVnUNpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTJ7Lkm5N{DPxE1?	MYrTRW5ITVJ?
HCT-116	NGfM[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTNyLkC1OFgh\|ryP	NX;hSYlwW0GQR1XS
S-117	NIrJdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXTVJZQUUN3ME2zNU4zOjV5IN88US=>	NX3PfIlzW0GQR1XS
NCI-H1693	NYDTd5dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTN\|Lk[1OFIh\|ryP	MV3TRW5ITVJ?
A427	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTN\|Lkm5O\|Yh\|ryP	NH7NR5ZUSU6JRWK=
HT-29	M2PTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3q2[WlEPTB;M{SuOlA{OiEQvF2=	MVTTRW5ITVJ?
P12-ICHIKAWA	NEX1SYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTN2Lke0PVEh\|ryP	MnrlV2FPT0WU
CAL-51	NHzuVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTN3LkC3NFkh\|ryP	MnLYV2FPT0WU
Ramos-2G6-4C10	M4i5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEKwPYJKSzVyPUO1MlI1OjVizszN	NEnCTVBUSU6JRWK=
SCH	Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\TclJnUUN3ME2zOk41OTd2IN88US=>	NFHC[GFUSU6JRWK=
SK-MEL-24	M3nJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4e3SmlEPTB;M{[uPVA1PCEQvF2=	NX\qfo9CW0GQR1XS
SW1573	NXvuSlJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTN6LkeyNVYh\|ryP	MU\TRW5ITVJ?
BALL-1	NXr5TpA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLOSIJ7UUN3ME2zPU4zOTJ7IN88US=>	MX3TRW5ITVJ?
BE-13	NGnSbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEP4V2JKSzVyPUO5MlMzQSEQvF2=	MoT1V2FPT0WU
GI-1	M{XHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTN7Lki2OFch\|ryP	MkjCV2FPT0WU
GOTO	M1P5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rOOGlEPTB;M{muPVE{QSEQvF2=	Mni0V2FPT0WU
A673	NUO2ZWR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jadmlEPTB;NEGuNFM1OyEQvF2=	MWjTRW5ITVJ?
KG-1	NH7pUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;EdWxxUUN3ME20N{4{QTRizszN	MlHhV2FPT0WU
GP5d	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPRXFNyUUN3ME20OE4xPjZ4IN88US=>	MUTTRW5ITVJ?
MFM-223	MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HYe2lEPTB;NESuNVIzQCEQvF2=	MkXEV2FPT0WU
OAW-42	M3TGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHtN2ptUUN3ME20OE4zPjR\|IN88US=>	MnLKV2FPT0WU
C8166	NInCfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHGzWlhKSzVyPUS1MlA5OjJizszN	M3fH[3NCVkeHUh?=
LU-99A	NUj3TFFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTR4LkGzNlIh\|ryP	NXXtO5lYW0GQR1XS
NCI-H23	NGLtXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnI[oMxUUN3ME20Ok4yPzh3IN88US=>	NECzc3NUSU6JRWK=
HO-1-N-1	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXsWWlKSzVyPUS3MlA6QThizszN	NVLuWmNPW0GQR1XS
A3-KAW	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIr3RY5KSzVyPUS3MlExODdizszN	MUjTRW5ITVJ?
CGTH-W-1	M2O1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETuUIZKSzVyPUS3MlUxPjlizszN	NXv1OFM1W0GQR1XS
DJM-1	M1\MSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1T6cmlEPTB;NEeuOVQyOyEQvF2=	Ml\OV2FPT0WU
A101D	NYnyfGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDtSHNKSzVyPUS3MlY{PTdizszN	NEnKNWtUSU6JRWK=
BB30-HNC	MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHETWM2OD12OD6zNFczKM7:TR?=	NX3WPGZkW0GQR1XS
T98G	NFHETIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrQV5RKUUN3ME20PE41PjN\|IN88US=>	MUHTRW5ITVJ?
NCI-H1573	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLaTWM2OD12OT60OFYzKM7:TR?=	NHXGdmdUSU6JRWK=
MEG-01	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33FeGlEPTB;NEmuO\|QyOSEQvF2=	NEHld25USU6JRWK=
WM-115	NVPsO\|IxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvETWM2OD12OT65NlIzKM7:TR?=	M{XKWnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western Blot	DR5/CHOP; PubMed: 25531448 PLoS One (A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5. γH2AX/H2AX; PubMed: 22933245 EMBO Mol Med FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX. pATM; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 53BP1; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. NF-kB; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. pS6/S6; PubMed: 24831086 Oncotarget HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies.	25531448 22933245 27686740 24831086
Immunofluorescence	DNA damage; PubMed: 27686740 Cell Cycle (A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX). γH2AX; PubMed: 28069876 Mol Cancer Ther Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.	27686740 28069876
Growth inhibition assay	Cell viability ; PubMed: 25531448 PLoS One A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.	25531448
ELISA	IL-8; PubMed: 28456021 Virology ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. GLP-1; PubMed: 29392078 Aging Dis Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.	28456021 29392078

In vivo

Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. ^[1] Olaparib shows great response to Brca1^-/-;p53^-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad^-/-;p53^-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. ^[3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. ^[4]

Protocol

Kinase Assay: ^[1]	+ Expand FlashPlate assay (96-well screening assay): To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl₂,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD⁺ final assay concentration, and 0.075 μCi ³H-NAD⁺ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research: ^[1]	+ Expand Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D Concentrations: 1-300 nM Incubation Time: 7-14 days Method: The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: Brca1^-/-;p53^-/- mammary tumors are generated in K14cre;Brca1^F/F;p53^F/F mice. Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS Dosages: 50 mg/kg Administration: Administered via i.p. injection at 10 μL/g of body weight (Only for Reference)

References

[4] Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.

+ Expand

Solubility (25°C)

In vitro	DMSO	86 mg/mL warmed (197.94 mM)
	Water	0.002 mg/mL (0.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Molecular Weight	434.46
Formula	C₂₄H₂₃FN₄O₃
CAS No.	763113-22-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04024254	Not yet recruiting	Drug: Folic Acid Tablet	Ovarian Cancer\|Breast Cancer\|Folic Acid Deficiency	Rush University Medical Center	August 2019	Phase 2\|Phase 3
NCT04005690	Recruiting	Drug: Cobimetinib\|Drug: Olaparib	Resectable Pancreatic Ductal Adenocarcinoma\|Stage 0 Pancreatic Cancer AJCC v8\|Stage I Pancreatic Cancer AJCC v8\|Stage IA Pancreatic Cancer AJCC v8\|Stage IB Pancreatic Cancer AJCC v8\|Stage II Pancreatic Cancer AJCC v8\|Stage IIA Pancreatic Cancer AJCC v8\|Stage IIB Pancreatic Cancer AJCC v8\|Stage III Pancreatic Cancer AJCC v8	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	August 1 2019	Phase 2
NCT03786796	Recruiting	Drug: Olaparib	Renal Cell Carcinoma\|Metastatic Renal Cell Carcinoma\|Kidney Cancer\|Renal Carcinoma\|Kidney Cancer Metastatic	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca	June 3 2019	Phase 2
NCT03745950	Not yet recruiting	Drug: Olaparib Oral Capsule\|Drug: Placebo oral capsule	Endometrial Carcinoma	ARCAGY/ GINECO GROUP	February 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to prepare the solution of the compound (S1060) for in vivo study?
Answer:
We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.
Question 2:
I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?
Answer:
For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.
Question 3:
How long can the chemical compound be stable in DMEM at 4 °C?
Answer:
The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

Related PARP Products

G007-LK ^New

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025 ^New

NU1025 is a potent PARP inhibitor with IC50 of 400 nM.
SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Veliparib (ABT-888)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Rucaparib (AG-014699,PF-01367338) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Features:The first PARP inhibitor used in clinical trials combined with temozolomide.
Talazoparib (BMN 673)

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.
PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).
AG-14361

AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.
A-966492

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 187 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 187 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)